Park Place Capital Corp Has $169,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Park Place Capital Corp lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 29.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 2,580 shares of the company’s stock after selling 1,062 shares during the period. Park Place Capital Corp’s holdings in AstraZeneca were worth $169,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. McClarren Financial Advisors Inc. boosted its holdings in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in AstraZeneca during the third quarter worth about $28,000. Albion Financial Group UT grew its position in AstraZeneca by 68.9% in the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after purchasing an additional 248 shares in the last quarter. Groupama Asset Managment increased its stake in AstraZeneca by 22.9% in the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after buying an additional 101,225 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in shares of AstraZeneca during the 3rd quarter worth approximately $45,000. 20.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on AZN. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, AstraZeneca presently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Trading Up 0.4 %

NASDAQ:AZN opened at $68.20 on Thursday. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The stock’s fifty day moving average price is $66.20 and its two-hundred day moving average price is $74.32. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The company has a market cap of $211.49 billion, a P/E ratio of 32.63, a P/E/G ratio of 1.13 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.87 EPS. As a group, analysts expect that AstraZeneca PLC will post 4.12 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.